Condition: Carrier State · Pancreatic Disease · Kidney Diseases · Sponsor: Philip Polgreen
The overarching hypothesis is that CF carriers are at increased risk for developing most of the extrapulmonary conditions associated with CF compared to the general population. Specifically, it is hypothesized that this pilot data will detect subclinical evidence of pancreatic and kidney disorders among CF carriers. This will be determined by bringing CF carriers and controls to the CRU for one visit where they will answer survey questions and undergo laboratory testing. Additionally, they will collect urine and stool samples at home that will be sent to outside laboratories for testing.
This description comes directly from the study's public registry record.
Philip M Polgreen, MD · (319) 384-6194 · philip-polgreen@uiowa.edu
Shelby L Francis, PhD · 319-678-8037 · shelby-francis@uiowa.edu
Always discuss trial participation with your own doctor first.
| University of Iowa Hospitals and Clinics | Iowa City, Iowa, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05474417